Modality
Vaccine
MOA
KRASG12Ci
Target
FXIa
Pathway
Wnt
MyelofibrosisPsANSCLC
Development Pipeline
Preclinical
~Feb 2015
→ ~May 2016
Phase 1
~Aug 2016
→ ~Nov 2017
Phase 2
Feb 2018
→ Jul 2030
Phase 2Current
NCT06084329
1,860 pts·NSCLC
2020-06→2030-07·Terminated
NCT05694939
651 pts·NSCLC
2018-02→2029-04·Recruiting
2,511 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-04-143.0y awayPh3 Readout· NSCLC
2030-07-144.3y awayPh3 Readout· NSCLC
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2/3
Recruit…
P2/3
Termina…
Catalysts
Ph3 Readout
2029-04-14 · 3.0y away
NSCLC
Ph3 Readout
2030-07-14 · 4.3y away
NSCLC
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06084329 | Phase 2/3 | NSCLC | Terminated | 1860 | PANSS |
| NCT05694939 | Phase 2/3 | NSCLC | Recruiting | 651 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| Lisolucimab | Novartis | Approved | CD20 | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa |